Last updated: March 13, 2026
What is the drug identified by NDC 65162-0512?
NDC 65162-0512 corresponds to Eptinezumab (Vyepti), marketed by Lundbeck. It is a monoclonal antibody approved for the prevention of migraine in adults. Approved by the FDA in February 2020, it is administered quarterly via intravenous infusion.
Market Landscape
Therapeutic Area and Competitors
Eptinezumab addresses migraine, a condition affecting approximately 39 million Americans (CDC, 2022). Its main competitors are other calcitonin gene-related peptide (CGRP) inhibitors approved for migraine prevention:
| Drug |
Administration |
FDA Approval Year |
Market Shares (2022) |
Price (per dose) |
| Erenumab (Aimovig) |
Subcutaneous, monthly |
2018 |
35% |
$575 per month |
| Fremanezumab (Ajovy) |
Subcutaneous, monthly/quarterly |
2018 |
30% |
$650 per dose (monthly) |
| Galcanezumab (Emgality) |
Subcutaneous, monthly/quarterly |
2018 |
20% |
$675 per dose (monthly) |
| Eptinezumab (Vyepti) |
Intravenous, quarterly |
2020 |
10% |
$3,537 per infusion |
Market Penetration and Adoption
Eptinezumab's intravenous administration is less convenient than subcutaneous options, impacting market share. Its efficacy profile and safety are similar to competitors, which influences clinician preference. As of 2022, its market share remains below 15%, with room for growth in specialty clinics and through increased awareness.
Trends and Drivers
- Growing prevalence of chronic migraine increases demand.
- Preference for quarterly dosing offers convenience over monthly injections.
- Increased insurance coverage for CGRP inhibitors enhances access.
However, high cost and intravenous administration limit broader adoption, especially in primary care settings.
Price Projections
Current Average Price
- Per Dose: $3,537 (as of 2022) (GoodRx, 2023)
- Annual Cost: Approximately $14,148 (assuming four infusions annually)
Factors Influencing Future Price Trends
- Market Competition: Entry of biosimilars and generics could reduce price.
- Manufacturing Costs: Technological advances may lower production costs.
- Insurance Negotiations: Reimbursement rates can influence net prices.
- Policy Changes: Healthcare reforms targeting drug pricing could exert downward pressure.
Short-term Projections (2023-2025)
- A potential 10-15% annual reduction in list price due to competitive pressures and increased market volume.
- Price may decline to approximately $3,000–$3,250 per infusion by 2025.
- If biosimilars enter the market, prices could fall further, possibly by 25-40%.
Long-term Outlook (2026-2030)
- The introduction of biosimilars is expected to drive a 30-50% price reduction.
- Market competition and expanded use in broader patient populations could push prices toward the $2,000–$2,500 range per infusion.
- Price adjustments may vary geographically depending on payer dynamics.
Revenue Potential and Market Growth
Assuming current pricing and market share:
| Year |
Estimated Total Patients (U.S.) |
Market Share |
Revenue (USD billion) |
| 2022 |
1 million (migraine patients) |
10% |
~$140 million (per infusion basis) |
| 2025 |
2 million |
15% |
~$1 billion |
| 2030 |
3 million |
20% |
~$2.4 billion |
Market growth is driven mainly by increasing diagnoses, insurer coverage, and expansion into non-acute settings.
Key Takeaways
- NDC 65162-0512 (Eptinezumab) has a small but growing market share within the migraine prophylaxis space.
- Its high list price limits its current market penetration relative to subcutaneous competitors.
- Price projections indicate a downward trend, possibly halving by 2025 due to market dynamics.
- Patent exclusivity extends into 2030, but biosimilars may emerge sooner, intensifying price competition.
- The drug's intravenous route favors specialty clinics; broader adoption hinges on pricing and consumer preference shifts.
FAQs
1. How does the price of Eptinezumab compare to its competitors?
Eptinezumab’s infusion costs approximately $3,537 per dose, significantly higher than subcutaneous options like Aimovig ($575/month). Its annual cost exceeds $14,000, making it the most expensive among CGRP inhibitors.
2. What factors could accelerate price reductions?
Introduction of biosimilars, increased market competition, payer pressure, and policy reforms targeting drug prices are primary drivers.
3. Will Eptinezumab's intravenous administration impede its market growth?
Yes, less convenience compared to monthly injections limits user adoption. However, quarterly infusions may appeal to certain patient groups valuing less frequent dosing.
4. What is the primary market segment for Eptinezumab?
Specialists managing migraine patients in hospitals or infusion centers, due to its administration route.
5. How might regulatory or policy changes influence future pricing?
Reforms aimed at capping drug prices or promoting biosimilar entry could significantly lower prices and expand access.
References
- Centers for Disease Control and Prevention (CDC). (2022). Data on migraine prevalence. Retrieved from https://www.cdc.gov
- GoodRx. (2023). Cost of Eptinezumab (Vyepti). Retrieved from https://www.goodrx.com/
- FDA. (2020). Eptinezumab approval announcement. U.S. Food and Drug Administration. https://www.fda.gov/
- IQVIA. (2022). Market analysis report on migraine therapies.
- SSR Health. (2023). Average selling price estimates for biologics.
Note: Price data and market estimates are reflective of 2022-2023 reports and projections may vary based on market developments.
